Gland Pharma Limited
All news and filings related to Gland Pharma Limited.
View all news & filings- Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meetings in June 2026
Gland Pharma Limited will hold investor meetings in June 2026. Meetings are scheduled with Carnelian Asset Management on June 01, 2026, and with ICICI Securities on June 08, 2026, as part of the India Investor Conference 2026.
Read the summary - Medium impact
Gland Pharma Q4 FY26 Earnings Call Transcript Released
Gland Pharma released its Q4 FY26 earnings call transcript. Q4 FY26 revenues grew 22% YoY to ₹17,428 million. Full year FY26 revenues increased 14.5% to ₹64,307 million. The CDMO segment saw 28% growth, contributing 46% of total revenues. Cenexi achieved EBITDA positive status. Capex of ₹2,000 crore planned over five years.
Read the summary - Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meetings in May 2026
Gland Pharma will conduct analyst and institutional investor meetings in May 2026. Scheduled meetings include Carnelian Asset Management on May 21, 360 ONE Capital on May 27, and Ashmore Investment Management on May 29. The schedule is subject to change.
Read the summary - Low impact
Gland Pharma Announces Audited Financial Results for FY26
Gland Pharma Limited announced its Audited Financial Results for the financial year ended March 31, 2026. The Board approved the standalone and consolidated results on May 15, 2026. The detailed results are available on the company's website and stock exchange platforms.
Read the summary - Low impact
Gland Pharma: Earnings Call Recording for Q4 FY26 Uploaded
Gland Pharma has uploaded the audio recording of its earnings call for Q4 FY26, held on May 15, 2026. The recording is available on the company's website.
Read the summary - Low impact
Gland Pharma Grants 690,019 Stock Options to 124 Employees Under ESOP 2025
Gland Pharma granted 690,019 stock options to 124 employees under its ESOP 2025 scheme. Options vest over three years starting May 15, 2027. Exercise prices are ₹934.15 for 455,413 options and ₹1 for 234,606 options.
Read the summary - Medium impact
Gland Pharma Recommends Final Dividend of ₹20/Share; AGM on Aug 25
Gland Pharma's Board approved Q4 and FY26 results with an unmodified audit opinion. A final dividend of ₹20 per share is recommended. The record date is August 11, 2026. The 48th AGM is scheduled for August 25, 2026.
Read the summary - High impact
Gland Pharma Q4 FY26 Investor Presentation: Revenue Up 22%, Adj. PAT Up 97%
Gland Pharma reported Q4 FY26 consolidated revenue of ₹17,428 crore, up 22% YoY. Adj. PAT surged 97% to ₹3,667 crore. FY26 revenue was ₹64,307 crore, up 14%, with Adj. PAT at ₹10,455 crore, up 50%. The company launched five molecules in the US in Q4 FY26 and plans facility upgrades in August 2026. A final dividend of ₹20 per share is recommended.
Read the summary - High impact
Gland Pharma Q4FY26: Revenue up 22% to ₹17,428 crore, PAT surges 97%
Gland Pharma reported Q4 FY26 consolidated revenue of ₹17,428 crore, up 22% YoY. PAT surged 97% to ₹3,667 crore. Full year FY26 revenue grew 14.5% to ₹64,307 crore. The company recommended a final dividend of ₹20 per share.
Read the summary - Medium impact
Gland Pharma Recommends Final Dividend of ₹20/share, Sets August 11 Record Date
Gland Pharma's Board approved Q4 FY26 results with an unmodified auditor's report. A final dividend of ₹20 per share is recommended for FY26, with August 11, 2026, as the record date. The 48th AGM is scheduled for August 25, 2026.
Read the summary - Medium impact
Gland Pharma Reappoints Naina Lal Kidwai as Independent Director
Gland Pharma Limited shareholders have reappointed Ms. Naina Lal Kidwai as an Independent Director for a second term, effective May 17, 2026, to May 16, 2031. Shareholders also approved remuneration for her role.
Read the summary - Medium impact
Gland Pharma: Special Resolution to Reappoint Naina Lal Kidwai as Independent Director Passed
Gland Pharma Limited's postal ballot results confirm the special resolution to reappoint Ms. Naina Lal Kidwai as Independent Director passed with 94.18% votes in favour. The e-voting period was from April 14 to May 13, 2026.
Read the summary - Low impact
Gland Pharma to consider ESOP grant on May 15, 2026
Gland Pharma Limited will hold an ESOP Compensation Committee meeting on May 15, 2026, to consider and approve the grant of stock options under its ESOP 2025 scheme.
Read the summary - Low impact
Gland Pharma clarifies remuneration for Independent Director Naina Lal Kidwai
Gland Pharma clarified reappointment of Ms. Naina Lal Kidwai as Independent Director. Members' approval via special resolution will be sought annually if her remuneration exceeds 50% of total Non-Executive Director remuneration for FY2026-27 to FY2030-31.
Read the summary - Low impact
Gland Pharma Schedules Q4 FY26 Earnings Conference Call for May 15, 2026
Gland Pharma Limited announced its Q4 FY26 earnings conference call scheduled for May 15, 2026. The call will discuss financial performance and business updates for the fiscal year ended March 31, 2026. Audio recordings and transcripts will be available on the company website.
Read the summary - Low impact
Gland Pharma: Newspaper Notice on Postal Ballot Dispatch and E-voting
Gland Pharma published a newspaper notice on April 14, 2026, regarding the dispatch of its Postal Ballot Notice and e-voting information. The company seeks member approval to reappoint Ms. Naina Lal Kidwai as an Independent Director. Remote e-voting is open from April 14 to May 13, 2026, with results due by May 15, 2026.
Read the summary - Low impact
Gland Pharma: Postal Ballot Notice for Reappointment of Independent Director and Remuneration
Gland Pharma is seeking member approval via postal ballot to reappoint Ms. Naina Lal Kidwai as an Independent Director for a second term (May 17, 2026 - May 16, 2031). The proposal also includes a commission of 0.25% on net profits, capped at ₹1 crore annually, as remuneration.
Read the summary - Low impact
Gland Pharma: No Share Dematerialization/Rematerialization Requests for Q4FY26
Gland Pharma Limited confirmed no share dematerialization or rematerialization requests were received for the quarter ended March 31, 2026. This is in accordance with SEBI (Depositories and Participants) Regulations, 2018.
Read the summary - Low impact
Gland Pharma Reappoints Naina Lal Kidwai as Independent Director for 5 Years
Gland Pharma's Board has reappointed Ms. Naina Lal Kidwai as an Independent Director for a second five-year term, effective May 17, 2026, to May 16, 2031. Member approval will be obtained via postal ballot and e-voting.
Read the summary - Low impact
Gland Pharma Appoints Prasadha Rao Lysetti as Sr. Vice-President (Head - Operations)
Gland Pharma Limited appointed Mr. Prasadha Rao Lysetti as Sr. Vice-President (Head - Operations) effective April 06, 2026. Lysetti has over 25 years of experience in pharmaceutical manufacturing and operations.
Read the summary - Low impact
Gland Pharma Publishes Newspaper Notice for Shareholder Communication
Gland Pharma Limited published a newspaper notice for shareholders regarding electronic communication of statutory documents. Shareholders are urged to update their email addresses with the RTA or Depository Participant to receive notices and reports electronically.
Read the summary - Low impact
Gland Pharma Closes Trading Window from March 28, 2026, for Q4 FY26 Results
Gland Pharma's trading window will be closed from March 28, 2026. The closure is in anticipation of the declaration of audited financial results for the quarter and financial year ending March 31, 2026. The exact date of the board meeting to approve these results will be announced later.
Read the summary - Low impact
Gland Pharma Schedules Analyst Meet on March 23, 2026
Gland Pharma Limited will hold a one-on-one meeting with Ventura Securities on March 23, 2026. This meeting is part of the company's investor engagement activities.
Read the summary - Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meetings from March 18-20, 2026
Gland Pharma Limited will conduct Analyst and Institutional Investor Meetings from March 18-20, 2026. The schedule includes Non-Deal Roadshows with Elara (USA) and one-on-one meetings. The company noted that the schedule is subject to change.
Read the summary - Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meet on March 16, 2026
Gland Pharma Limited will hold an analyst/institutional investor meeting with Sundaram Asset Management on March 16, 2026. This is part of ongoing investor relations activities. The schedule may be subject to change.
Read the summary - Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meetings from March 12-17, 2026
Gland Pharma will host analyst and institutional investor meetings from March 12 to March 17, 2026. Meetings include engagements with Investec, SBI Mutual Fund, and Capital World Investors. The schedule is subject to change.
Read the summary - Medium impact
Gland Pharma receives GST order for ₹6.3 Cr tax demand, interest, and penalty
Gland Pharma received a GST order for a tax demand of ₹5.03 Cr, ₹1.25 Cr penalty, and interest for FY 2019-20. The total disputed amount is ₹6.29 Cr. The company believes the demand is unjustified and will file an appeal, expecting no material financial impact.
Read the summary - Medium impact
Gland Pharma receives USFDA tentative approval for Brimonidine Tartrate Ophthalmic Solution
Gland Pharma received tentative USFDA approval for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC). The product is bioequivalent to Bausch & Lomb's Lumify. The US market for this product was approximately USD 39 million (₹323 crore) for the twelve months ending September 2025.
Read the summary - Medium impact
Gland Pharma CEO Shyamakant Giri Resigns, Effective April 30, 2026
Gland Pharma Limited's CEO, Shyamakant Giri, has resigned. His resignation was accepted by the board today and he will cease to be CEO and Key Management Personnel on April 30, 2026. The company thanked him for his contributions.
Read the summary - Low impact
Gland Pharma Grants 1,626 Stock Options to One Employee Under ESOP 2025
Gland Pharma granted 1,626 stock options to one employee under its ESOP 2025 scheme. The grant includes options priced at ₹897.40 and ₹1, with vesting scheduled over three years starting March 03, 2027.
Read the summary - Low impact
Gland Pharma to hold Group Meeting with Goldman Sachs on March 5, 2026
Gland Pharma Limited will hold a Group Meeting with Goldman Sachs on March 5, 2026. The schedule is subject to change.
Read the summary - Low impact
Gland Pharma to Hold One-on-One Meeting with Renaissance Investment Managers on Feb 25
Gland Pharma Limited will conduct a one-on-one meeting with Renaissance Investment Managers on February 25, 2026. This is part of the company's schedule of investor meetings.
Read the summary - Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meeting on Feb 23, 2026
Gland Pharma Limited will hold a one-on-one meeting with Mirae Asset Investment Managers on February 23, 2026. This engagement is part of the company's ongoing investor relations activities.
Read the summary - Low impact
Gland Pharma Appoints Dr. Jitendra Gangwal as VP (R&D)
Gland Pharma Limited has appointed Dr. Jitendra Gangwal as Vice-President (Research and Development), effective February 18, 2026. Dr. Gangwal has over 24 years of experience in pharmaceutical R&D and has developed over 55 products.
Read the summary - Low impact
Gland Pharma Schedules One-on-One Investor Meeting with Investec on Feb 12, 2026
Gland Pharma Limited will hold a one-on-one meeting with Investec on February 12, 2026. This is part of the company's ongoing investor engagement activities.
Read the summary - Medium impact
Gland Pharma Receives USFDA Approval for Zoledronic Acid Injection
Gland Pharma received USFDA approval for Zoledronic Acid Injection, 4 mg/100 mL Single-Dose Bags. The product is a generic alternative to InfoRLife's Zoledronic Acid Injection. The US market for this product was approximately USD 6.7 million for the twelve months ending November 2025.
Read the summary - Medium impact
Gland Pharma Q3 FY26 Earnings Call Transcript Released
Gland Pharma released its Q3 FY26 earnings call transcript. The company reported a 22% year-on-year revenue growth to INR 16,954 million and a 25% increase in adjusted EBITDA to INR 4,490 million. Strategic investments of INR 2,000 crore are planned over five years, focusing on capacity expansion and R&D. Cenexi showed a turnaround, meeting revenue targets.
Read the summary - Low impact
Gland Pharma Schedules Analyst/Institutional Investor Meetings from Feb 4-10, 2026
Gland Pharma Limited will hold investor meetings from February 4-10, 2026. The schedule includes a Non-Deal Roadshow with Motilal Oswal on Feb 4, and participation in conferences by JM Financial, Systematix, and Axis Capital.
Read the summary - Low impact
Gland Pharma COO Satnam Singh Loomba to Retire on March 31, 2026
Gland Pharma's Chief Operating Officer, Satnam Singh Loomba, will retire on March 31, 2026, due to superannuation. He has been with the company since May 1, 2024. The company has acknowledged his contributions.
Read the summary - Low impact
Gland Pharma: Newspaper Ad for Q3FY26 Unaudited Financial Results Published
Gland Pharma Limited published its Unaudited Financial Results for Q3FY26 and nine months ended December 31, 2025. The results were approved by the Board on January 28, 2026, and published in English and Telugu newspapers.
Read the summary - Low impact
Gland Pharma Uploads Q3 FY26 Earnings Call Recording to Website
Gland Pharma has uploaded the audio recording of its earnings call for Q3 FY26, which took place on January 28, 2026. The recording is available on the company's website.
Read the summary - High impact
Gland Pharma Q3 FY26: Revenue Up 22% YoY to ₹16,954 Crore, Adj. PAT Grows 37%
Gland Pharma reported Q3 FY26 revenue of ₹16,954 crore, up 22% YoY. Adjusted PAT increased by 37% to ₹2,797 crore. Adjusted EBITDA grew 25% to ₹4,490 crore. R&D expenses increased to ₹6.5 crore. The company launched nine molecules in the US.
Read the summary - High impact
Gland Pharma Q3 FY26 Results: Revenue up 22% YoY to ₹16,954 Crore, Adj. PAT up 37%
Gland Pharma reported Q3 FY26 consolidated revenue of ₹16,954 crore, up 22% YoY. Adjusted PAT rose 37% YoY to ₹2,797 crore. The US market grew 19% and Europe 54% YoY. M/s. Grant Thornton Bharat LLP was reappointed as Internal Auditors for FY26-27.
Read the summary - Low impact
Gland Pharma: Certificate Under SEBI (Depositories and Participants) Regulations, 2018 for Q3 FY25
Gland Pharma Limited submitted a confirmation certificate for the quarter ended December 31, 2025, under SEBI regulations. The certificate from its RTA, MUFG Intime India, confirms processing of dematerialised securities and adherence to listing and registration timelines.
Read the summary - Low impact
Gland Pharma to host Earnings Conference Call on Jan 28, 2026
Gland Pharma Limited will host an Earnings Conference Call on January 28, 2026, at 18:30 IST. The call will discuss financial performance and business updates for the quarter and nine months ended December 31, 2025. Transcripts and recordings will be available on the company website.
Read the summary - Medium impact
Gland Pharma Receives USFDA Approval for Olopatadine Hydrochloride Ophthalmic Solution
Gland Pharma has received USFDA approval for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The product is therapeutically equivalent to Alcon's Pataday Once Daily Relief, 0.7%, and is indicated for allergic conjunctivitis.
Read the summary - Low impact
Gland Pharma Closes Trading Window from Dec 27 for Q3 FY26 Results
Gland Pharma will close its trading window from December 27, 2025. This is in anticipation of the declaration of its unaudited financial results for the quarter and nine months ending December 31, 2025. The window will reopen 48 hours after the results are announced.
Read the summary - Low impact
Gland Pharma Schedules Investor Meeting on December 17, 2025
Gland Pharma Limited will hold a One-on-One Investor Meeting with Capital Research Global Investors on December 17, 2025. The schedule is subject to change.
Read the summary - Low impact
Gland Pharma Schedules One-on-One Investor Meeting on Dec 16, 2025
Gland Pharma Limited will conduct a one-on-one meeting with Panvira Investment Management on December 16, 2025. This is an update on the company's schedule for investor engagements.
Read the summary - Low impact
Gland Pharma Intimates Analyst/Institutional Investor Meetings
Gland Pharma Limited announced the schedule of Analyst/Institutional Investor Meetings. An investor meeting arranged by B&K Securities is scheduled for December 11, 2025.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio